Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 4, Issue 136, Pages 136ra70-136ra70
Publisher
American Association for the Advancement of Science (AAAS)
Online
2012-05-31
DOI
10.1126/scitranslmed.3003513
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia
- (2011) Leisl M. Packer et al. CANCER CELL
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
- (2011) Rafael B. Blasco et al. CANCER CELL
- DDR1 Receptor Tyrosine Kinase Promotes Prosurvival Pathway through Notch1 Activation
- (2011) Hyung-Gu Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- A MEK-independent role for CRAF in mitosis and tumor progression
- (2011) Ainhoa Mielgo et al. NATURE MEDICINE
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- BRAF, a target in melanoma
- (2010) Keith T. Flaherty et al. CANCER
- BRAF Inactivation Drives Aneuploidy by Deregulating CRAF
- (2010) T. Kamata et al. CANCER RESEARCH
- Targets of Raf in tumorigenesis
- (2010) T. S. Niault et al. CARCINOGENESIS
- The Brothers RAF
- (2010) Lawrence N. Kwong et al. CELL
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer
- (2010) B. Sen et al. CLINICAL CANCER RESEARCH
- Acute Insulin Signaling in Pancreatic Beta-Cells Is Mediated by Multiple Raf-1 Dependent Pathways
- (2010) Emilyn U. Alejandro et al. ENDOCRINOLOGY
- The essence of senescence
- (2010) T. Kuilman et al. GENES & DEVELOPMENT
- Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Faye M. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
- (2010) Jiannong Li et al. Nature Chemical Biology
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
- (2010) O. E. Sturm et al. Science Signaling
- Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding
- (2009) B. Sen et al. CANCER RESEARCH
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
- (2009) Martin L. Sos et al. JOURNAL OF CLINICAL INVESTIGATION
- CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
- (2008) K S M Smalley et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now